// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1151 Abstracts

All you need to know about kidney disease in antiphospholipid syndrome

M. Tektonidou - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Thrombotic microangiopathy

Hydroxychloroquine

All-cause mortality and cardiovascular death in hydroxychloroquine users in rheumatoid arthritis patients – a population based danish cohort study

K. Soeltoft - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Aminaphtone increases skin blood perfusion and improves clinical symptoms in patients with raynaud’s phenomenon independently from different treatment backgrounds

B. Ruaro - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Raynaud syndrome

Hydroxychloroquine

Antimalarials protective effects in systemic lupus erythematosus in china

F. Wang - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Characterisation of monocyte populations in peripheral blood of sle patients

S.M. Anderson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Concordance with latest guidelines for dmard screening and monitoring in secondary care

E. Cefai - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Congenital heart blockand maternal positive anti-ro and anti-la autoantibodies: a single centre-study

I. Añón Oñate - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Cytokine production by activated plasmacytoid dendritic cells and nk cells is suppressed by an irak4 inhibitor

K. Hjorton - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Development and validation of clinical predictors for inadequate response to treat-to-target methotrexate therapy in newly diagnosed ra patients

X.M. Teitsma - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Dosage of hydroxychloroquine (PLAQUENIL online survey by patient organisation nvle

Z. Osmani - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

Hydroxychloroquine

Early and sustained remission in sle can be achieved by using pulse methyl-prednisolone, hidroxychloroquine and low-medium dose-prednisone

B.R. Ruiz Estévez - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Essdai domain evaluation of primary sjÖgren’s syndrome (PSS patients enrolled in two independent poc studies indicates differential utility of domains for trial inclusion and composite endpoints in pss trials

T. Dörner - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

Hydroxychloroquine

How to manage asymptomatic carriers of antiphospholipid antibodies

L. Andreoli - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Hydroxychloroquine has no protective effect on the development of systemic lupus erythematosus in 7004 patients with primary sjÖgren’s syndrome: a nationwide population-based study

B.-C. Hsu - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Hydroxychloroquine inhibits soluble cd154 production through ca2+ and pkc signalling pathway

C.H. Tung - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Hydroxychloroquine may help to improve the in vitro fertilization-embryo transfer outcomes in ana and ds-dna positive patients

F. Lian - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Hydroxychloroquine reduces risk of incident diabetes mellitus in primary sjÖgren syndrome patients: a propensity score matched population-based cohort study

W.-S. Chen - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Diabetes

Hydroxychloroquine

Hyper ig-d syndrome treatment with hydroxychloroquine

M.P. Abi Saab - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Bacterial Skin Infection

Hydroxychloroquine

Less pain over 2 years with biological compared to conventional combination therapy in early rheumatoid arthritis: results from the randomised controlled swefot trial

T. Olofsson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Factors associated with poor therapeutic adherence to hydroxychloroquine during systemic lupus

Y. Rozban - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Copyright © 2026. QuantiNova All rights reserved